SCHEMBL6500763

SCHEMBL6500763

O=C(NC1CC2CC1CN2)c1ncc(-c2ccccc2Cl)o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.51
HDAC6 Q9UBN7 3/20 0.51
RAB9A P51151 6/20 0.38
NPC1 O15118 5/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 2/20 0.37
GAA P10253 2/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPT P10636 3/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
ACKR3 P25106 1/20 0.36
GHSR Q92847 2/20 0.36
CNR1 P21554 1/20 0.35
CASP3 P42574 2/20 0.34
SENP7 Q9BQF6 2/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496644 0.88 FAAH (0.46) HDAC1HDAC6RAB9ANPC1MEN1
SCHEMBL6488113 0.88 FAAH (0.47) HDAC1HDAC6RAB9ASMN1; SMN2GAA
SCHEMBL6497995 0.88 HDAC1 (0.51) HDAC1HDAC6ALDH1A1HPGDACKR3
SCHEMBL6500689 0.88 FAAH (0.47) HDAC1HDAC6ACKR3FAAH
SCHEMBL6499361 0.85 HDAC1 (0.53) HDAC1HDAC6RAB9ANPC1SMN1; SMN2
SCHEMBL6498706 0.85 TUBB4A (0.48) HDAC1HDAC6FAAH
SCHEMBL6498500 0.84 HDAC1 (0.48) HDAC1HDAC6ACKR3
SCHEMBL6496537 0.84 ALDH1A1 (0.41) HDAC1HDAC6MEN1KMT2ASMN1; SMN2
SCHEMBL6496470 0.82 FAAH (0.36) HDAC1HDAC6MEN1KMT2AHTT
SCHEMBL7232713 0.82 HDAC1 (0.48) HDAC1HDAC6RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 HDAC1 467/4885HDAC6 1069/4885RAB9A 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.